AAPL281.85-1.93 (-0.68%) ▼|ABBV255.27+1.92 (+0.76%) ▲|ABT92.83-1.29 (-1.37%) ▼|ACN125.04-3.94 (-3.05%) ▼|ADBE205.97+3.24 (+1.60%) ▲|AMAT697.48+70.64 (+11.27%) ▲|AMD536.72+15.14 (+2.90%) ▲|AMGN359.93+1.60 (+0.45%) ▲|AMT167.94-7.66 (-4.36%) ▼|AMZN240.09+7.40 (+3.18%) ▲|AVGO373.33+8.31 (+2.28%) ▲|AXP341.46+1.10 (+0.32%) ▲|BA215.26-1.99 (-0.92%) ▼|BAC58.04+0.16 (+0.28%) ▲|BKNG183.39+1.93 (+1.06%) ▲|BLK952.72-11.99 (-1.24%) ▼|BMY58.45+0.93 (+1.62%) ▲|BNY144.11+0.55 (+0.38%) ▲|BRK-B495.95-2.71 (-0.54%) ▼|C142.79+1.03 (+0.73%) ▲|CAT1,033.24+35.77 (+3.59%) ▲|CL91.98-0.09 (-0.10%) ▼|CMCSA24.44+1.27 (+5.46%) ▲|COF202.35-1.65 (-0.81%) ▼|COP104.43-1.53 (-1.44%) ▼|COST944.98-7.56 (-0.79%) ▼|CRM158.45+0.08 (+0.05%) ▲|CSCO117.47+3.70 (+3.25%) ▲|CVS103.36-0.98 (-0.94%) ▼|CVX168.84-2.22 (-1.30%) ▼|DE624.07+10.83 (+1.77%) ▲|DHR193.19-3.00 (-1.53%) ▼|DIS98.65-0.14 (-0.14%) ▼|DUK128.03-0.37 (-0.29%) ▼|EMR142.90-0.59 (-0.41%) ▼|FDX324.51+5.98 (+1.88%) ▲|GD348.45+1.74 (+0.50%) ▲|GE373.26+4.26 (+1.15%) ▲|GEV1,099.27+54.10 (+5.18%) ▲|GILD126.10-1.78 (-1.39%) ▼|GM77.52-0.59 (-0.75%) ▼|GOOG350.91+16.22 (+4.84%) ▲|GOOGL353.32+15.93 (+4.72%) ▲|GS1,023.93+4.32 (+0.42%) ▲|HD349.92+1.06 (+0.30%) ▲|HON227.58-15.84 (-6.51%) ▼|IBM277.65+6.02 (+2.22%) ▲|INTC130.38+2.06 (+1.61%) ▲|INTU267.20-0.52 (-0.19%) ▼|ISRG405.76+1.49 (+0.37%) ▲|JNJ257.94+3.28 (+1.29%) ▲|JPM330.84+1.79 (+0.54%) ▲|KO82.58-0.05 (-0.06%) ▼|LIN510.87-8.75 (-1.68%) ▼|LLY1,228.14+20.02 (+1.66%) ▲|LMT503.10-4.30 (-0.85%) ▼|LOW220.15-2.34 (-1.05%) ▼|LRCX409.83+30.74 (+8.11%) ▲|MA510.87+11.85 (+2.37%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.11-0.69 (-1.13%) ▼|MDT80.74-0.25 (-0.30%) ▼|META564.45+14.20 (+2.58%) ▲|MMM162.43-1.59 (-0.97%) ▼|MO73.85+0.06 (+0.08%) ▲|MRK129.36+0.70 (+0.54%) ▲|MS212.57+0.54 (+0.25%) ▲|MSFT368.04-4.93 (-1.32%) ▼|MU1,128.19-4.14 (-0.37%) ▼|NEE88.53-0.03 (-0.03%) ▼|NFLX73.88+0.07 (+0.09%) ▲|NKE41.32+0.57 (+1.40%) ▲|NOW99.83+1.49 (+1.52%) ▲|NVDA194.62+2.09 (+1.09%) ▲|ORCL148.25-0.28 (-0.19%) ▼|PEP138.10-3.29 (-2.33%) ▼|PFE24.41+0.12 (+0.49%) ▲|PG147.91-1.11 (-0.74%) ▼|PLTR116.21+3.28 (+2.90%) ▲|PM182.48+1.71 (+0.95%) ▲|QCOM187.52-1.88 (-0.99%) ▼|RTX187.74-0.25 (-0.13%) ▼|SBUX104.11-0.49 (-0.47%) ▼|SCHW90.52-0.16 (-0.17%) ▼|SO96.72-0.44 (-0.45%) ▼|SPG227.69+0.80 (+0.35%) ▲|T21.79-0.93 (-4.09%) ▼|TMO505.11-7.92 (-1.54%) ▼|TMUS173.83-8.86 (-4.85%) ▼|TSLA411.51+31.80 (+8.37%) ▲|TXN284.54-0.89 (-0.31%) ▼|UBER75.20-1.00 (-1.31%) ▼|UNH418.44-9.45 (-2.21%) ▼|UNP272.41+4.06 (+1.51%) ▲|UPS107.98-0.16 (-0.15%) ▼|USB61.40+0.49 (+0.80%) ▲|V342.23+6.00 (+1.78%) ▲|VZ44.09-2.45 (-5.26%) ▼|WFC83.84-0.03 (-0.03%) ▼|WMT114.83-0.86 (-0.74%) ▼|XOM136.09-0.46 (-0.33%) ▼|AAPL281.85-1.93 (-0.68%) ▼|ABBV255.27+1.92 (+0.76%) ▲|ABT92.83-1.29 (-1.37%) ▼|ACN125.04-3.94 (-3.05%) ▼|ADBE205.97+3.24 (+1.60%) ▲|AMAT697.48+70.64 (+11.27%) ▲|AMD536.72+15.14 (+2.90%) ▲|AMGN359.93+1.60 (+0.45%) ▲|AMT167.94-7.66 (-4.36%) ▼|AMZN240.09+7.40 (+3.18%) ▲|AVGO373.33+8.31 (+2.28%) ▲|AXP341.46+1.10 (+0.32%) ▲|BA215.26-1.99 (-0.92%) ▼|BAC58.04+0.16 (+0.28%) ▲|BKNG183.39+1.93 (+1.06%) ▲|BLK952.72-11.99 (-1.24%) ▼|BMY58.45+0.93 (+1.62%) ▲|BNY144.11+0.55 (+0.38%) ▲|BRK-B495.95-2.71 (-0.54%) ▼|C142.79+1.03 (+0.73%) ▲|CAT1,033.24+35.77 (+3.59%) ▲|CL91.98-0.09 (-0.10%) ▼|CMCSA24.44+1.27 (+5.46%) ▲|COF202.35-1.65 (-0.81%) ▼|COP104.43-1.53 (-1.44%) ▼|COST944.98-7.56 (-0.79%) ▼|CRM158.45+0.08 (+0.05%) ▲|CSCO117.47+3.70 (+3.25%) ▲|CVS103.36-0.98 (-0.94%) ▼|CVX168.84-2.22 (-1.30%) ▼|DE624.07+10.83 (+1.77%) ▲|DHR193.19-3.00 (-1.53%) ▼|DIS98.65-0.14 (-0.14%) ▼|DUK128.03-0.37 (-0.29%) ▼|EMR142.90-0.59 (-0.41%) ▼|FDX324.51+5.98 (+1.88%) ▲|GD348.45+1.74 (+0.50%) ▲|GE373.26+4.26 (+1.15%) ▲|GEV1,099.27+54.10 (+5.18%) ▲|GILD126.10-1.78 (-1.39%) ▼|GM77.52-0.59 (-0.75%) ▼|GOOG350.91+16.22 (+4.84%) ▲|GOOGL353.32+15.93 (+4.72%) ▲|GS1,023.93+4.32 (+0.42%) ▲|HD349.92+1.06 (+0.30%) ▲|HON227.58-15.84 (-6.51%) ▼|IBM277.65+6.02 (+2.22%) ▲|INTC130.38+2.06 (+1.61%) ▲|INTU267.20-0.52 (-0.19%) ▼|ISRG405.76+1.49 (+0.37%) ▲|JNJ257.94+3.28 (+1.29%) ▲|JPM330.84+1.79 (+0.54%) ▲|KO82.58-0.05 (-0.06%) ▼|LIN510.87-8.75 (-1.68%) ▼|LLY1,228.14+20.02 (+1.66%) ▲|LMT503.10-4.30 (-0.85%) ▼|LOW220.15-2.34 (-1.05%) ▼|LRCX409.83+30.74 (+8.11%) ▲|MA510.87+11.85 (+2.37%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.11-0.69 (-1.13%) ▼|MDT80.74-0.25 (-0.30%) ▼|META564.45+14.20 (+2.58%) ▲|MMM162.43-1.59 (-0.97%) ▼|MO73.85+0.06 (+0.08%) ▲|MRK129.36+0.70 (+0.54%) ▲|MS212.57+0.54 (+0.25%) ▲|MSFT368.04-4.93 (-1.32%) ▼|MU1,128.19-4.14 (-0.37%) ▼|NEE88.53-0.03 (-0.03%) ▼|NFLX73.88+0.07 (+0.09%) ▲|NKE41.32+0.57 (+1.40%) ▲|NOW99.83+1.49 (+1.52%) ▲|NVDA194.62+2.09 (+1.09%) ▲|ORCL148.25-0.28 (-0.19%) ▼|PEP138.10-3.29 (-2.33%) ▼|PFE24.41+0.12 (+0.49%) ▲|PG147.91-1.11 (-0.74%) ▼|PLTR116.21+3.28 (+2.90%) ▲|PM182.48+1.71 (+0.95%) ▲|QCOM187.52-1.88 (-0.99%) ▼|RTX187.74-0.25 (-0.13%) ▼|SBUX104.11-0.49 (-0.47%) ▼|SCHW90.52-0.16 (-0.17%) ▼|SO96.72-0.44 (-0.45%) ▼|SPG227.69+0.80 (+0.35%) ▲|T21.79-0.93 (-4.09%) ▼|TMO505.11-7.92 (-1.54%) ▼|TMUS173.83-8.86 (-4.85%) ▼|TSLA411.51+31.80 (+8.37%) ▲|TXN284.54-0.89 (-0.31%) ▼|UBER75.20-1.00 (-1.31%) ▼|UNH418.44-9.45 (-2.21%) ▼|UNP272.41+4.06 (+1.51%) ▲|UPS107.98-0.16 (-0.15%) ▼|USB61.40+0.49 (+0.80%) ▲|V342.23+6.00 (+1.78%) ▲|VZ44.09-2.45 (-5.26%) ▼|WFC83.84-0.03 (-0.03%) ▼|WMT114.83-0.86 (-0.74%) ▼|XOM136.09-0.46 (-0.33%) ▼|
30.9 C
New York
Monday, June 29, 2026

Tag: study

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Australian Telecoms Sector Disconnected by Data Security and Incomplete Data

Appian research reveals that 90% of telcos have invested in digital solutions but data security and access hurdles remain SYDNEY, June 24, 2025 /PRNewswire/ --...

Orcoda Transforms Waipā District Council’s Fleet Management, Driving Efficiency and Sustainability

Integrated Logistics Software Solution Enhances Vehicle Utilisation, Staff Satisfaction, and Operational Transparency for 165-Vehicle Fleet. BRISBANE, Australia, June 24, 2025 /PRNewswire/ -- Orcoda (ASX: ODA), a...

E-Invoicing Could Unlock Over A$22 Billion for the Australian Economy, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in Australia and across five other major markets Productivity...

METALLIC MINERALS ANNOUNCES C$5M BEST EFFORTS PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. NOT AN OFFER OF SECURITIES FOR SALE IN THE...

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership...

PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the “Board”) has approved a deferral of the previously announced record date of May 2, 2025 for the Company’s previously announced dividend of Scilex preferred stock (the “Dividend”) to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be such later date to be determined in the sole discretion of the Board (such later record date as so determined by the Board, the “New Record Date”). The Board retains the right to continue to change any New Record Date (and therefore any related payment date for the Dividend) and the ability to revoke the Dividend.

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for ROMVIMZA™ (vimseltinib)

LOUISVILLE, Ky., June 23, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a specialty pharmacy partner by Deciphera Pharmaceuticals, LLC for ROMVIMZA (vimseltinib), which has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.1 This indication was approved based on the Phase III MOTION study of ROMVIMZA in patients with tenosynovial giant cell tumor (TGCT).2

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

Savvas Offers K-12 Educators Free Access to Robust Science of Reading Resources

On-demand webinars presented by leading literacy experts now available on the Savvas Science of Reading Digital Bookshelf, just in time for summer learning PARAMUS, N.J.,...

Simple Divorce Releases New Study on Impact of Economic Factors on Divorce Rates in Ontario

Toronto, Ontario, June 23, 2025 (GLOBE NEWSWIRE) -- A recent study from Simple Divorce has uncovered a compelling connection between financial stress and increasing divorce rates across Ontario. The findings shine a spotlight on how inflation, job insecurity, housing costs, and overall economic uncertainty are placing heightened pressure on marriages, leading many couples to part ways.

Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion

ASPIRE pivotal Level-1 PMA IDE study evaluated PearlMatrix vs. local autograft in single-level TLIF procedures:- Demonstrated statistically superior fusion speed;- Achieved over twice as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy